ITEMS IN AFP WITH KEYWORD:
In patients with established CV disease and type 2 diabetes, the addition of empagliflozin to standard therapy reduces all-cause mortality and CV mortality. This is notable because empagliflozin is the only drug other than metformin to demonstrate a mortality benefit, albeit for a fairly narrow group of patients.
The American Heart Association (AHA) and American Diabetes Association (ADA) joined together to release statements on preventing CVD in persons with diabetes.
Review key screening recommendations for type 2 diabetes in nonpregnant adults, pregnant women, children, and older persons. Learn which test results are considered diagnostic.
Jan 15, 2016 Issue
Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in adults aged 40 to 70 years who are overweight or obese. Clinicians should offer or refer patients with abnormal blood glucose to intensive behavioral counseling interventions to promote a healthful diet and physical activity.
The glass half full is that sitagliptin does not increase the risk of cardiovascular events in patients with type 2 diabetes. The glass half empty is that it does not reduce the risk, either. And that is the important message: In patients with a mean glycated hemoglobin level of 7.2%, adding sitagli...
Clinicians need to consider the best available research findings, their own experience, and their patients' needs and values.
Review the key components of diabetes treatment, including nutrition, exercise, and pharmacologic therapies. Metformin is the first-line choice of hypoglycemic agents to reduce mortality and complications. Learn which A1C goals are most appropriate for patients.
Dapagliflozin will lower A1C levels by an average of 0.7 percentage points when used alone or by an average of 0.5 percentage points when added to metformin therapy. Its effect on diabetes-associated morbidity and mortality has not been studied, and although it is well tolerated, there is an associa...
This statement from American and European diabetes societies suggests that tighter control of hyperglycemia be attempted only in patients with a recent diagnosis and a low risk of hypoglycemia; who have a long life expectancy with few or no comorbidities, including cardiovascular disease; and who ar...
Jun 1, 2015 Issue
Tight Glycemic Control for Type 2 Diabetes Mellitus (Over Five Years) [Medicine by the Numbers]
Studies show that none were helped and 1 in 6 patients were harmed. See why.